Given that SATB1 levels are dysregulated in various cancers, including lymphoma, with a further link to PD‐1 regulation, our study can be of relevance to anti‐PD‐1 immunotherapies in cancer clinical trials. This evidence concerns the gene SATB1 and cancer.